{"hands_on_practices": [{"introduction": "The transformation of a proto-oncogene into an oncogene often begins with the disruption of its molecular \"on/off\" switch. In this exercise, we will model this fundamental process using the *RAS* protein, a key signaling hub, as our example. By applying principles of chemical kinetics, you will derive and use a mathematical relationship to quantify how a specific cancer-causing mutation alters the balance between the protein's active and inactive states, providing a concrete link between a genetic change and its biochemical consequence [@problem_id:5068807].", "problem": "A central activation mechanism for the Rat Sarcoma viral oncogene homolog (RAS) small guanosine triphosphatase (GTPase) is nucleotide cycling between an inactive guanosine diphosphate (GDP)-bound state and an active guanosine triphosphate (GTP)-bound state. In a minimal two-state model with constant total RAS, GDP-to-GTP loading is driven by guanine nucleotide exchange factors (GEFs) and is treated as a first-order process with rate constant $k_{L}$, while GTP hydrolysis back to GDP is treated as a first-order process with rate constant $k_{H}$ that includes intrinsic hydrolysis and stimulation by GTPase-activating proteins (GAPs). Assume a constant supply of nucleotides so that $k_{L}$ and $k_{H}$ are time-independent. Let $[R_{T}]$ be the constant total concentration of RAS, and denote $[R_{\\mathrm{GTP}}]$ and $[R_{\\mathrm{GDP}}]$ as the concentrations of the GTP- and GDP-bound states, respectively.\n\nStarting from mass-action kinetics and the steady-state condition (no net accumulation of $[R_{\\mathrm{GTP}}]$), derive an expression for the steady-state fraction of RAS in the GTP-bound state, $f_{\\mathrm{GTP}} = \\frac{[R_{\\mathrm{GTP}}]}{[R_{T}]}$, as a function of $k_{L}$ and $k_{H}$. Then, using the numerical values $k_{L} = 8.0 \\times 10^{-2}\\,\\mathrm{s}^{-1}$ and $k_{H} = 4.0 \\times 10^{-2}\\,\\mathrm{s}^{-1}$ for the wild-type protein, compute $f_{\\mathrm{GTP}}$ for wild-type and for the glycine-to-valine substitution at position 12 (G12V) that reduces $k_{H}$ by a factor of $10$ while leaving $k_{L}$ unchanged.\n\nExpress the final answer as two dimensionless decimal fractions in a single row matrix, with the wild-type value first and the G12V value second. Round each value to four significant figures. Do not use a percentage sign.", "solution": "The problem asks for the derivation of the steady-state fraction of active RAS and its calculation for two cases: wild-type and a G12V mutant.\n\n1.  **Set up the kinetic model.** The system involves two states, $R_{\\mathrm{GDP}}$ (inactive) and $R_{\\mathrm{GTP}}$ (active), with first-order transitions. The rate of change for the concentration of the active state, $[R_{\\mathrm{GTP}}]$, is given by mass-action kinetics:\n    $$ \\frac{d[R_{\\mathrm{GTP}}]}{dt} = (\\text{rate of formation}) - (\\text{rate of consumption}) = k_L [R_{\\mathrm{GDP}}] - k_H [R_{\\mathrm{GTP}}] $$\n\n2.  **Apply the steady-state condition.** At steady state, the concentration of each state is constant, so $\\frac{d[R_{\\mathrm{GTP}}]}{dt} = 0$. This implies that the rate of formation equals the rate of consumption:\n    $$ k_L [R_{\\mathrm{GDP}}]_{\\mathrm{ss}} = k_H [R_{\\mathrm{GTP}}]_{\\mathrm{ss}} $$\n\n3.  **Use the conservation equation.** The total concentration of RAS, $[R_T]$, is constant and is the sum of the concentrations of the two states: $[R_T] = [R_{\\mathrm{GTP}}] + [R_{\\mathrm{GDP}}]$. We can express $[R_{\\mathrm{GDP}}]$ in terms of the other variables: $[R_{\\mathrm{GDP}}] = [R_T] - [R_{\\mathrm{GTP}}]$.\n\n4.  **Solve for the active fraction, $f_{\\mathrm{GTP}}$**. Substitute the conservation relation into the steady-state equation:\n    $$ k_L ([R_T] - [R_{\\mathrm{GTP}}]_{\\mathrm{ss}}) = k_H [R_{\\mathrm{GTP}}]_{\\mathrm{ss}} $$\n    Rearranging to solve for $[R_{\\mathrm{GTP}}]_{\\mathrm{ss}}$:\n    $$ k_L [R_T] = k_H [R_{\\mathrm{GTP}}]_{\\mathrm{ss}} + k_L [R_{\\mathrm{GTP}}]_{\\mathrm{ss}} = (k_L + k_H) [R_{\\mathrm{GTP}}]_{\\mathrm{ss}} $$\n    The desired fraction is $f_{\\mathrm{GTP}} = \\frac{[R_{\\mathrm{GTP}}]_{\\mathrm{ss}}}{[R_T]}$. Dividing the above equation by $[R_T]$ and $(k_L + k_H)$ gives the general expression:\n    $$ f_{\\mathrm{GTP}} = \\frac{k_L}{k_L + k_H} $$\n\n5.  **Calculate $f_{\\mathrm{GTP}}$ for wild-type (WT) RAS.** Using the given rate constants:\n    $k_L = 8.0 \\times 10^{-2}\\,\\mathrm{s}^{-1}$ and $k_H = 4.0 \\times 10^{-2}\\,\\mathrm{s}^{-1}$.\n    $$ f_{\\mathrm{GTP, WT}} = \\frac{8.0 \\times 10^{-2}}{8.0 \\times 10^{-2} + 4.0 \\times 10^{-2}} = \\frac{8.0 \\times 10^{-2}}{12.0 \\times 10^{-2}} = \\frac{8}{12} = \\frac{2}{3} \\approx 0.6667 $$\n\n6.  **Calculate $f_{\\mathrm{GTP}}$ for the G12V mutant.** The loading rate $k_L$ is unchanged. The hydrolysis rate $k_H$ is reduced by a factor of 10:\n    $k_{H, \\mathrm{G12V}} = \\frac{4.0 \\times 10^{-2}}{10} = 4.0 \\times 10^{-3}\\,\\mathrm{s}^{-1}$.\n    $$ f_{\\mathrm{GTP, G12V}} = \\frac{8.0 \\times 10^{-2}}{8.0 \\times 10^{-2} + 4.0 \\times 10^{-3}} = \\frac{0.08}{0.08 + 0.004} = \\frac{0.08}{0.084} = \\frac{80}{84} = \\frac{20}{21} \\approx 0.9524 $$\n\nThe final answer consists of the two fractions, rounded to four significant figures: 0.6667 (wild-type) and 0.9524 (G12V).", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.6667  0.9524\n\\end{pmatrix}\n}\n$$", "id": "5068807"}, {"introduction": "While point mutations are a common mechanism of oncogene activation, they are not the only way. Large-scale genomic rearrangements, such as chromosomal translocations, can create entirely new \"fusion genes\" with potent oncogenic activity. This practice challenges you to act as a molecular pathologist, interpreting data from modern genomic assays—RNA sequencing and DNA copy number analysis—to solve a classic case in cancer genetics involving the *BCR–ABL1* fusion [@problem_id:5068834]. This exercise hones your ability to synthesize disparate data types to uncover the precise molecular driver of a malignancy.", "problem": "A tumor sample is profiled with Ribonucleic Acid sequencing (RNA-seq) and genome-wide Deoxyribonucleic Acid (DNA) copy-number analysis. The RNA-seq reveals junction reads consistent with a Breakpoint Cluster Region (BCR)–Abelson Proto-Oncogene 1 (ABL1) fusion in the e13a2 configuration, that is, BCR exon 13 joined to ABL1 exon 2. The DNA copy-number across the BCR locus on chromosome 22 and the ABL1 locus on chromosome 9 is neutral (approximately diploid, 2 copies) with no focal gains or losses. No separate point mutations are detected in the ABL1 kinase domain by this assay.\n\nStarting from the Central Dogma (DNA $\\rightarrow$ RNA $\\rightarrow$ protein) and the core definitions of proto-oncogene activation mechanisms (e.g., increased gene dosage, regulatory dysregulation, structural alteration creating constitutive activity), reason which activation mechanism most parsimoniously explains the observed data. Then infer the expected qualitative impact on downstream signaling pathway behavior in terms of dependency on extracellular cues and pathway persistence. Consider the canonical pathways downstream of ABL1, including Rat Sarcoma virus (RAS)/Mitogen-Activated Protein Kinase (MAPK), Phosphoinositide 3-Kinase (PI3K)/Protein Kinase B (AKT), and Janus Kinase (JAK)/Signal Transducer and Activator of Transcription (STAT).\n\nWhich option best matches the mechanism and downstream impact?\n\nA. Increased ABL1 activity arises from gene amplification, elevating kinase dosage; signaling remains ligand-dependent and primarily triggers transient RAS/MAPK bursts.\n\nB. A chromosomal translocation creates a BCR–ABL1 fusion (p210 from e13a2) that constitutively activates the tyrosine kinase via BCR-driven oligomerization and loss of ABL1 auto-inhibition, producing persistent, growth factor–independent activation of RAS/MAPK, PI3K/AKT, and JAK/STAT pathways.\n\nC. Promoter hypomethylation of BCR upregulates transcription, but signaling still requires cytokine receptor dimerization; downstream effects are confined to JAK/STAT with minimal RAS/MAPK engagement.\n\nD. A truncating event eliminates the ABL1 ATP-binding site, reducing kinase activity and dampening downstream signaling; the RNA-seq junction is a nonfunctional byproduct.\n\nE. Enhancer hijacking causes overexpression of wild-type ABL1 without structural change; kinase output cycles between active and inactive states in response to integrin signals, yielding only mild, copy-number–neutral MAPK activation.", "solution": "The problem asks for the most parsimonious explanation for the observed molecular data and its downstream consequences.\n\n1.  **Analyze the Genomic and Transcriptomic Data.** The RNA-seq data definitively shows a *BCR–ABL1* fusion transcript. This means the two genes, normally on different chromosomes (9 and 22), have been joined at the DNA level to form a single transcriptional unit. The DNA copy-number data shows that both the *BCR* and *ABL1* loci are diploid (2 copies), ruling out gene amplification as the cause. The most parsimonious explanation for a fusion gene with no change in copy number is a balanced chromosomal translocation, specifically the t(9;22) translocation that creates the Philadelphia chromosome.\n\n2.  **Determine the Activation Mechanism.** The problem states there are no point mutations. The activation of the ABL1 kinase is due to the creation of the novel fusion protein. The ABL1 protein normally has an N-terminal region that keeps the kinase domain in an inactive, auto-inhibited state. In the BCR–ABL1 fusion, this inhibitory region is replaced by a segment of the BCR protein which contains a coiled-coil domain. This domain causes the fusion proteins to oligomerize (cluster together), which forces the ABL1 kinase domains into close proximity, allowing them to activate each other via trans-autophosphorylation. This results in a kinase that is constitutively active, i.e., \"always on.\"\n\n3.  **Infer the Impact on Downstream Signaling.** A constitutively active kinase like BCR–ABL1 will continuously phosphorylate its downstream targets, uncoupling the signaling pathways from the need for external growth factors. The major pathways downstream of ABL1 that promote cell proliferation and survival are the RAS/MAPK, PI3K/AKT, and JAK/STAT pathways. Therefore, the expected outcome is persistent, growth factor-independent activation of all these pathways.\n\n4.  **Evaluate the Options.**\n    *   A is incorrect: It claims gene amplification (ruled out by data) and ligand-dependent signaling (incorrect for this fusion).\n    *   B is correct: It accurately identifies the translocation, the mechanism of constitutive activation (oligomerization and loss of auto-inhibition), and the persistent, multi-pathway downstream effects.\n    *   C is incorrect: It proposes an epigenetic mechanism that cannot create a fusion transcript.\n    *   D is incorrect: It proposes a loss-of-function, which is the opposite of oncogenic activation.\n    *   E is incorrect: It claims no structural change, contradicting the fusion data.\n\nTherefore, option B provides the best and most complete explanation.", "answer": "$$\\boxed{B}$$", "id": "5068834"}, {"introduction": "Once an oncogenic mutation is identified, a critical next step is to determine its prevalence within the tumor. A tumor is a complex ecosystem of cells, and not all cancer cells may carry the same mutations. This exercise introduces you to the quantitative side of cancer genomics, where you will use sequencing data—specifically the variant allele fraction (VAF)—along with an estimate of tumor purity to infer a mutation's clonal status [@problem_id:5068857]. Mastering this calculation allows you to deduce whether a mutation was an early, foundational event in the tumor's evolution or a later addition, a distinction with profound implications for understanding cancer biology and guiding treatment.", "problem": "A surgically resected colorectal adenocarcinoma is profiled by targeted deep sequencing. At the proto-oncogene Kirsten rat sarcoma viral oncogene homolog (KRAS) locus, a Gly12Asp point mutation (G12D) is detected with an observed variant allele fraction (VAF) of $0.35$. Pathology and computational deconvolution estimate the tumor purity to be $0.70$, meaning a fraction $p=0.70$ of the DNA in the sample originates from tumor cells, with the remaining fraction $1-p$ from admixed normal tissue. Shallow whole-genome copy-number profiling indicates no copy-number alteration (CNA) at the KRAS locus in either the tumor or the normal compartment, so both compartments are diploid at this locus.\n\nUse only fundamental definitions:\n- Variant allele fraction (VAF) at a locus is the proportion of allelic reads carrying the variant among all reads at that locus in the bulk sample.\n- Tumor purity $p$ is the fraction of DNA originating from tumor cells.\n- Let $f$ denote the cancer cell fraction, the proportion of tumor cells that carry the KRAS mutation.\n- Let $m$ denote the mutant allele multiplicity, the number of mutant copies per mutated tumor cell at the locus.\n- Assume the normal cells do not carry the mutation.\n\nStarting from these definitions and the assumption of diploidy in both compartments at the locus, derive the general relationship linking the observed VAF $V$, the purity $p$, the cancer cell fraction $f$, and the mutant multiplicity $m$. Then, using the measured $V=0.35$, $p=0.70$, and assuming a heterozygous state at the locus ($m=1$) with no copy-number alteration, compute the inferred cancer cell fraction $f$. Provide your final answer as a single real number. If no rounding is necessary, give the exact value.", "solution": "The problem asks to derive a formula relating Variant Allele Fraction (VAF), tumor purity, and cancer cell fraction, and then to calculate the cancer cell fraction ($f$) for the given data.\n\n1.  **Derive the general formula.** The VAF ($V$) is the ratio of mutant allele reads to total allele reads in a bulk sample. We can model the expected counts of alleles from the different cell populations. The sample consists of a fraction $p$ of tumor cells and a fraction $(1-p)$ of normal cells.\n\n    *   **Total Alleles:** Both normal and tumor cells are diploid at this locus (ploidy = 2). The total number of alleles in the sample is proportional to the weighted average of the ploidy across the populations:\n        Total Alleles $\\propto (1-p) \\times 2 + p \\times 2 = 2 - 2p + 2p = 2$.\n\n    *   **Mutant Alleles:** The mutation is only in the tumor cells. Within the tumor fraction $p$, a sub-fraction $f$ of cells carry the mutation (the cancer cell fraction). Each of these mutated cells has $m$ copies of the mutant allele (the mutant allele multiplicity). The normal cells have 0 mutant alleles. The number of mutant alleles in the sample is proportional to:\n        Mutant Alleles $\\propto p \\times f \\times m$.\n\n    *   **VAF Formula:** The VAF is the ratio of mutant alleles to total alleles:\n        $$ V = \\frac{p \\times f \\times m}{2} $$\n        This is the general relationship for a diploid locus.\n\n2.  **Solve for the Cancer Cell Fraction ($f$).** Rearrange the formula to isolate $f$:\n    $$ f = \\frac{2V}{pm} $$\n\n3.  **Substitute the given values.** The problem provides:\n    *   Observed VAF, $V = 0.35$.\n    *   Tumor purity, $p = 0.70$.\n    *   The mutation is a heterozygous point mutation in a diploid region. This means in a mutated cell, there is 1 mutant allele and 1 wild-type allele. Therefore, the mutant allele multiplicity is $m=1$.\n\n    Now, substitute these values into the rearranged formula:\n    $$ f = \\frac{2 \\times 0.35}{0.70 \\times 1} $$\n    $$ f = \\frac{0.70}{0.70} $$\n    $$ f = 1 $$\n\nThe calculated cancer cell fraction is 1. This result indicates that the KRAS G12D mutation is clonal, meaning it is present in 100% of the tumor cells within the sample. This is typical for an early \"driver\" mutation that initiated tumor growth.", "answer": "$$\n\\boxed{1}\n$$", "id": "5068857"}]}